Management

Barry D. Quart, Pharm.D.
Chief Executive Officer and Director

Robert H. Rosen
President and Director

Kimberly J. Manhard
Executive VP, Drug Development

Paul Blake, FRCP
Chief Medical Officer

Robert E. Hoffman
Chief Financial Officer and Senior VP, Finance

David L. Szekeres
Senior VP, General Counsel, Business Development and Corporate Secretary

Thomas B. Ottoboni, Ph.D.
Senior VP, Pharmaceutical and Preclinical Research and Development

Anita Gupta D.O., Pharm.D.
Senior VP, Medical Strategy and Government Affairs

John C. Arthur, Ph.D.
VP, Manufacturing & Supply

Sean T. Ristine
VP, Human Resources


Barry D. Quart, Pharm.D.
Chief Executive Officer and Director

Barry D. Quart, Pharm.D. has served as a director of Heron since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through May 2013 and as a director through its acquisition by AstraZeneca PLC in June 2012. Previously, he was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer's La Jolla Laboratories. Prior to Pfizer's acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva BioPharma Corp. from June 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in June 2015. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.

Back to top

Robert H. Rosen
President and Director

Robert H. Rosen has served as a director of Heron since July 2012. Mr. Rosen was appointed President in May 2013, and prior to that, served as our Senior Vice President and Chief Commercial Officer since October 2012. Mr. Rosen has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and commercializing pharmaceutical products. From March 2012 to October 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life science advisory firm. From April 2011 to March 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals, where he was responsible for the development of the oncology business unit for regions that included the Americas, Europe, Japan and Asia Pacific. During his tenure at Bayer, Mr. Rosen led the launch of Nexavar® (sorafenib) for the treatment of renal cell carcinoma and hepatocellular carcinoma. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc., where he was responsible for the development of Sanofi's U.S. oncology business and the launch of Eloxatin® (oxaliplatin) for colon cancer. Mr. Rosen has been a director of La Jolla Pharmaceutical Company since July 2014. From November 2014 to December 2015, Mr. Rosen served as a director of Conkwest, Inc. (now NantKwest, Inc.). Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.

Back to top

Kimberly J. Manhard
Executive VP, Drug Development

Kimberly J. Manhard joined us as Executive Vice President, Drug Development in January 2016. Ms. Manhard served as a director of Heron from January 2014 until she joined the management team. Ms. Manhard has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations. From May 2008 to January 2016, Ms. Manhard served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at Ardea, Ms. Manhard was instrumental in the development and December 2015 regulatory approval of Zurampic® (lesinurad) for the treatment of hyperuricemia associated with gout. Prior to joining Ardea in 2006, Ms. Manhard was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc. and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including Viracept® (nelfinavir). She was also previously with Bristol Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol® (paclitaxel) and infectious disease compounds, including Videx® (didanosine) and Zerit® (stavudine). Ms. Manhard began her industry career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance, Inc.). Ms. Manhard received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.

Back to top

Paul Blake, FRCP
Chief Medical Officer

Paul Blake joined us as Chief Medical Officer in December 2017. Dr. Blake has more than 30 years of experience in clinical research and medical affairs. Prior to joining Heron, Dr. Blake served as Senior Vice President of Clinical, Medical, and Regulatory Affairs at BioDelivery Sciences International, Inc., since January 2017. From September 2014 to September 2016, Dr. Blake served as Chief Development Officer at Oxford BioMedica. From August 2007 to April 2014, Dr. Blake served as Chief Medical Officer and Senior Vice President of Clinical Research and Development at Aeterna Zentaris Inc. Dr. Blake has also held various leadership positions in biopharmaceutical companies, including Cephalon, Inc. and SmithKline Beecham Pharmaceuticals. Over his career, Dr. Blake has been involved in over 40 NDAs and sNDAs, including products for the treatment of pain such as Relafen® (nabumetone), a nonsteroidal anti-inflammatory drug that reduces hormones that cause pain and inflammation, and Fentora® (fentanyl), an opioid pain medication. Other drugs that Dr. Blake has been involved in developing include Kytril® (granisetron), Tenormin® (atenolol), Zestril® (lisinopril), Paxil® (paroxetine), Coreg® (carvedilol), Havrix® (hepatitis A vaccine), Hycamtin® (topotecan), Famvir® (famciclovir), Requip® (ropinirole), Avandia® (rosiglitazone), Provigil® (modafinil). Dr. Blake is qualified in medicine from the Royal Free Hospital School of Medicine, London University. He is a Fellow of the Royal College of Physicians, a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, and a Fellow of the American College of Clinical Pharmacology.

Back to top

Robert E. Hoffman
Chief Financial Officer and Senior VP, Finance

Robert E. Hoffman joined us as Chief Financial Officer and Senior Vice President, Finance in April 2017. Prior to joining Heron, Mr. Hoffman served as Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a biopharmaceutical company, since September 2016. Prior to Innovus Pharmaceuticals, Inc., Mr. Hoffman was Chief Financial Officer of AnaptysBio, Inc., a biopharmaceutical company, from July 2015 until September 2016. He was part of the founding management team of Arena Pharmaceuticals, Inc. in 1997, a biopharmaceutical company, ultimately serving as Senior Vice President, Finance and Chief Financial Officer until March 2011, and then again from August 2011 until July 2015. From March 2011 to August 2011, he served as Chief Financial Officer for Polaris Group, a biopharmaceutical company. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, Kura Oncology, Inc., a biopharmaceutical company, and MabVax Therapeutics Holdings, Inc., a biopharmaceutical company. He also is a member of the Financial Accounting Standards Board’s Small Business Advisory Committee and is a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman received his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.

Back to top

David L. Szekeres
Senior VP, General Counsel, Business Development and Corporate Secretary

David L. Szekeres joined us as Senior Vice President, General Counsel, Business Development and Corporate Secretary in March 2016. Mr. Szekeres has more than 15 years of legal and industry experience. From February 2014 to December 2015, Mr. Szekeres served as General Counsel, Chief Business Officer, Principal Financial Officer, and Corporate Secretary at Regulus Therapeutics, Inc. In that role, Mr. Szekeres played a critical role in overseeing the company’s business, financial and legal responsibilities as it developed into a clinical-stage corporation. From 2008 through its acquisition by Thermo Fisher Scientific Inc. in 2014, Mr. Szekeres served as Head of Mergers and Acquisitions, Securities and Governance at Life Technologies Corporation. From 2001 to 2006, Mr. Szekeres served as Corporate Attorney at a number of law firms, including O’Melveny & Myers LLP and Latham & Watkins LLP. Prior to 2001, Mr. Szekeres served as Senior Associate in Investment Banking at investment bank Robertson Stephens. Mr. Szekeres received a B.A. degree from the University of California, Irvine and a J.D. degree from Duke University School of Law.

Back to top

Thomas B. Ottoboni, Ph.D.
Senior VP, Pharmaceutical and Preclinical Research and Development

Thomas B. Ottoboni, Ph.D. joined us as Vice President of Pharmaceutical Development in March 2012 and was promoted to Senior Vice President of Pharmaceutical and Preclinical Research and Development in July 2014. Dr. Ottoboni has more than 20 years of drug development experience. From 2010 until 2011, Dr. Ottoboni was Vice President of Research and Development at Talima Therapeutics, Inc., where he worked on the development of a drug delivery implant to treat onychomycosis. From 1996 to 2008, Dr. Ottoboni served as Executive Vice President of Strategy and Operations at POINT Biomedical Corp., where he developed several imaging and drug delivery systems. From May 1994 through July 1996, Dr. Ottoboni served as Manager of Systems Development and Drug Delivery Research for InSite Vision, Inc., where he developed ophthalmic pharmaceutical delivery systems. He previously served as Director of Drug Delivery at Vitaphore Corp. Dr. Ottoboni is an inventor on more than 20 U.S. patents in organic and macromolecular chemistry. He received a B.S. degree in chemistry and a Ph.D. in organic chemistry from the University of California, Berkeley.

Back to top

Anita Gupta D.O., Pharm.D.
Senior VP, Medical Strategy and Government Affairs

Anita Gupta, D.O., Pharm.D. joined us as Senior Vice President of Medical Strategy and Government Affairs in August 2017 and is a board-certified anesthesiologist and internationally recognized pain specialist. Prior to joining Heron Therapeutics, Dr. Gupta was appointed as Vice Chair, Division of Pain Medicine and Regional Anesthesiology in the Department of Anesthesiology and Perioperative Medicine at Drexel University College of Medicine and Assistant Professor, Division of Pain Medicine at the University of Pennsylvania. Dr. Gupta also served as an anesthesiologist at both Johns Hopkins University and Washington Hospital Center. She is a member of the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and also a member of the board of directors of Amorsa Therapeutics, Inc., a biopharmaceutical company. Dr. Gupta received a B.S. degree and a Pharm.D. degree from Rutgers University College of Pharmacy, and a D.O. degree from the University of Medicine & Dentistry of New Jersey. She completed a residency in anesthesiology at Georgetown University, a fellowship in interventional pain management at Johns Hopkins University, and clinical scientist training in toxicology at the National Institutes of Health.

Back to top

John C. Arthur, Ph.D
VP, Manufacturing & Supply

John C. Arthur, Ph.D., joined us as Vice President of Manufacturing and Supply in April 2017. Prior to joining Heron Therapeutics, Dr. Arthur was Vice President of Manufacturing and CMC at Mast Therapeutics, Inc., a biopharmaceutical company, from June 2013 to October 2016, where he led all CMC activities for multiple Phase 2 and Phase 3 clinical programs. Prior to Mast Therapeutics, Dr. Arthur was Senior Director of Manufacturing at Auspex Pharmaceuticals, Inc., a biopharmaceutical company, and held several positions of increasing responsibility at various biopharmaceutical companies, including Cadence Pharmaceuticals, Inc., Kanisa Pharmaceuticals, Inc., Salmedix, Inc., Prometheus Laboratories, Inc., Maxim Pharmaceuticals, Inc., and Ionis Pharmaceuticals. Dr. Arthur received a B.S. in Biochemistry from Western Washington University, a Ph.D. in organic chemistry from the University of South Carolina, Columbia, and conducted his postdoctoral research at Michigan State University.

Back to top

Sean T. Ristine
VP, Human Resources

Sean T. Ristine joined us as Senior Director of Human Resources in August 2014 and was promoted to Vice President of Human Resources in September 2015. Mr. Ristine has more than 20 years of experience in human resources and business leadership. From September 2009 to August 2014, Mr. Ristine held key Human Resources positions at Cadence Pharmaceuticals, Inc., most recently as Senior Director of Human Resources and was instrumental in that function as Cadence grew to a commercial-stage company with over 200 employees located throughout the U.S. From 2004 through 2009, Mr. Ristine held Human Resources management roles of increasing responsibility at Kyocera Wireless Corp., including Director of Human Resources and Facilities. Prior to this, from 1995 to 2004, Mr. Ristine held positions at Kyocera America, Inc. including Manager of Human Resources. Mr. Ristine received a B.S. degree in Business and Organization Behavior from Brigham Young University and an M.B.A degree with an emphasis in Human Resources Management from San Diego State University.

Back to top